The Psychiatric Rehabilitation Approach to Weight Loss

Status Completed

Clinical Trial Summary

The primary aim of the project is to examine the efficacy of the Psychiatric Rehabilitation Weight Loss program in reduction of weight and body mass index (BMI.

Clinical Trial Description

The study involves 144 individuals who will be randomly assigned to the intervention group or treatment as usual group(control group). All Participants will undergo baseline assessment, assessment at week 12, week 24 and in year from baseline. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00572247
Study type	Interventional
Source	University of Kansas Medical Center
Contact
Status	Completed
Phase	N/A
Start date	January 2007
Completion date	December 2010

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04608032` - Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia	N/A
Terminated	`NCT00660595` - Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose	Phase 3
Completed	`NCT02655172` - Have a Good Grasp of the Worldthe World	N/A
Completed	`NCT01606436` - A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia	Phase 1
Completed	`NCT01729650` - Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor)	N/A
Completed	`NCT02525315` - Interest of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Auditory Hallucinations	Phase 2
Completed	`NCT00488319` - Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.	Phase 3
Completed	`NCT00088491` - Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia	Phase 3
Completed	`NCT01279213` - Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia	Phase 4
Completed	`NCT00600756` - Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone	Phase 3
Completed	`NCT00491569` - Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia	Phase 2
Completed	`NCT00328276` - Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia	Phase 2
Completed	`NCT00485823` - Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia	Phase 4
Active, not recruiting	`NCT00161408` - Psychological Intervention for Relapse Prevention in First Episode Schizophrenia	N/A
Terminated	`NCT05164289` - Interest of EMDR Schizophrenic Disorders
Withdrawn	`NCT00276263` - Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia	Phase 2
Completed	`NCT00088465` - Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder	Phase 3
Withdrawn	`NCT02654405` - Sodium Butyrate For Improving Cognitive Function In Schizophrenia	Phase 2/Phase 3
Completed	`NCT02544516` - Upside Down, Give me the Handle	N/A
Completed	`NCT00960219` - D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia	Phase 2